other material
confidence high
sentiment positive
materiality 0.60
Elicio Therapeutics receives $2.6M grant from GI Research Foundation for two cancer vaccines
Elicio Therapeutics, Inc.
- Grant awarded on Sept 7, 2023, adds to $2.8M received in Sept 2022 from GIRF.
- Funds will advance ELI-007 (mutant BRAF-peptide) and ELI-008 (p53 hotspot mutation-peptide) vaccines.
- Vaccines use Elicio's AMP lymph node-targeting platform; CMC, regulatory, and clinical prep underway.
- BRAF V600E mutations seen in 40% melanoma, 10% colon, 2% lung; p53 mutations in ~30% solid tumors.
- Non-dilutive funding supports IND planning and initial patient clinical assessment.